US007378097B2

(12) **United States Patent**
Glenn et al.

(10) **Patent No.: US 7,378,097 B2**
(45) **Date of Patent: *May 27, 2008**

(54) **USE OF PENETRATION ENHANCERS AND BARRIER DISRUPTION METHODS TO ENHANCE THE IMMUNE RESPONSE OF ANTIGEN AND ADJUVANT**

(75) Inventors: **Gregory M. Glenn**, Cabin John, MD (US); **Carl R. Alving**, Bethesda, MD (US)

(73) Assignee: **The United States of America as represented by the Secretary of the Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/790,715**

(22) Filed: **Mar. 3, 2004**

(65) **Prior Publication Data**

US 2008/0063696 A1 Mar. 13, 2008

Related U.S. Application Data

(63) Continuation of application No. 09/257,188, filed on Feb. 25, 1999, now Pat. No. 6,797,276, and a continuation-in-part of application No. PCT/US97/21324, filed on Nov. 14, 1997, now abandoned, and a continuation-in-part of application No. 08/896,085, filed on Jul. 17, 1997, now Pat. No. 5,980,898, which is a continuation-in-part of application No. 08/749,164, filed on Nov. 14, 1996, now Pat. No. 5,910,306.

(60) Provisional application No. 60/086,251, filed on May 21, 1998, provisional application No. 60/075,856, filed on Feb. 25, 1998, provisional application No. 60/075,850, filed on Feb. 25, 1998.

(51) **Int. Cl.**
A61K 45/00 (2006.01)

(52) **U.S. Cl.** **424/184.1**; 424/234.1; 424/447; 424/449

(58) **Field of Classification Search** 424/278.1, 424/184.1
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,837,340	A	9/1974	Counter
3,948,263	A	4/1976	Drake
3,964,482	A	6/1976	Gerstel
3,982,536	A	9/1976	Krogseng
4,196,191	A	4/1980	Almeida
4,220,584	A	9/1980	Limjuco
4,235,871	A	11/1980	Papahadjopoulos
4,285,931	A	8/1981	Limjuco
4,394,448	A	7/1983	Szoka
4,411,888	A	10/1983	Klipstein
4,455,142	A	6/1984	Martins
4,484,923	A	11/1984	Amkraut
4,497,796	A	2/1985	Salser
4,587,044	A	5/1986	Miller
4,692,462	A	9/1987	Banerjee
4,725,271	A	2/1988	Korol
4,732,892	A	3/1988	Sarpotdar
4,743,588	A	5/1988	Mirejovsky
4,761,372	A	8/1988	Maas
4,764,381	A	8/1988	Bodor
4,775,361	A	10/1988	Jacques
4,783,450	A	11/1988	Fawzi
4,810,499	A	3/1989	Nuwayser
4,834,985	A	5/1989	Elger
4,876,278	A	10/1989	Taylor
4,877,612	A	10/1989	Berger
4,892,737	A	1/1990	Bodor
4,908,389	A	3/1990	Mahjour
4,917,688	A	4/1990	Nelson
4,917,895	A	4/1990	Lee
4,921,757	A	5/1990	Wheatley
4,929,442	A	5/1990	Powell
4,946,853	A	8/1990	Bannon
4,956,171	A	9/1990	Chang
4,960,771	A	10/1990	Rajadhyaksha
4,970,206	A	11/1990	Alexander
5,003,987	A	4/1991	Grinwald
5,008,050	A	4/1991	Cullis
5,008,111	A	4/1991	Bodor

(Continued)

FOREIGN PATENT DOCUMENTS

AU	47099/89	6/1990

(Continued)

OTHER PUBLICATIONS

Kuby, 2000, Immunology, 4th ed. p. 47-53.*

(Continued)

Primary Examiner—Christina Chan
Assistant Examiner—Yunsoo Kim
(74) *Attorney, Agent, or Firm*—Morgan, Lewis & Bockius LLP

(57) **ABSTRACT**

A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.

108 Claims, 5 Drawing Sheets